Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 31;12(8):1014.
doi: 10.3390/brainsci12081014.

A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder

Affiliations

A Paradigm for Targeting Functional Impairment as an Outcome in Attention-Deficit/Hyperactivity Disorder

Margaret Danielle Weiss. Brain Sci. .

Abstract

Although functional impairment is required for a diagnosis in the DSM 5, the time frame and definition of functional impairment is ambiguous. We present a conceptual review clarifying the difference between functional impairment as a stable trait representing strength or disability in various domains, and functional impairment as secondary to emotional or behavior problems, which is a state sensitive to change with treatment intervention. Functional impairment as a measure of treatment outcome includes both change from baseline and status at the endpoint of treatment. When using a validated measure of function, functional improvement can be defined as the percentage of patients who achieve the Minimal Important Clinical Difference (MCID) and functional remission as the percentage of patients who normalize at treatment endpoint. True treatment remission should be defined as both symptomatic and functional remission.

Keywords: ADHD; attention deficits; endpoint treatment; functional impairment; hyperactivity; measurement; outcome; rating scales; remission.

PubMed Disclaimer

Conflict of interest statement

The author declares a conflict of interest in discussing measurement of functional impairment, in that she is the author of the WFIRS scale described in that section and receives royalties from Multi-Health Systems. Weiss has received consultant fees from Adlon, CBPartners, Tris, and Putnam Associates. She has been on the Advisory board of Idorsia and Revibe.

Similar articles

Cited by

References

    1. Pyles D.A., Muniz K., Cade A., Silva R. A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Res. Dev. Disabil. 1997;18:185–214. doi: 10.1016/S0891-4222(97)00003-6. - DOI - PubMed
    1. McCabe R., Healey P. Miscommunication in Doctor-Patient Communication. Top. Cogn. Sci. 2018;10:409–424. doi: 10.1111/tops.12337. - DOI - PMC - PubMed
    1. Jacob K.S. Patient experience and the psychiatric discourse: Attempting to bridge incommensurable worlds. Indian J. Psychiatry. 2015;57:423–426. doi: 10.4103/0019-5545.171847. - DOI - PMC - PubMed
    1. Gordon M., Antshel K., Faraone S., Barkley R., Lewandowski L., Hudziak J.J., Biederman J., Cunningham C. Symptoms vs. Impairment. ADHD Rep. 2005 doi: 10.1521/adhd.2005.13.4. - DOI - PubMed
    1. Barkley R.A., Cunningham C.E., Gordon M., Faraone S.V., Lewandowski L., Murphy K.R. ADHD Symptoms vs. Impairment: Revisited. ADHD Rep. 2006;14:1–9. doi: 10.1521/adhd.2006.14.2.1. - DOI

LinkOut - more resources